←
Matthew Rabinowitz365 posts
Matthew Rabinowitz avatar✓

Matthew Rabinowitz ✓

@MattRVerse

Biotech, Healthcare, AI, Security, Founder & investor @NateraGenetics, @MyOmeinc, @NatureEye, Medici Therapeutics | R&D Leader of the Year 2024

◷ Joined April 2022▧ 62 Photos and videos
Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Nov 6

This week marks an important moment for Natera. I founded the company with a simple belief: every family deserves access to technologies that offer early detection of disease. Roughly twenty years later, I’m incredibly proud of what this company has become. I want to thank Steve Chapman for his excellent leadership. Since joining Natera in 2010, and as CEO since 2019, Steve helped grow Natera from a prenatal testing company into a global leader in precision medicine across women’s health, oncology and organ health. His impact on our business, our team and millions of patients will last for years. We’re thrilled to welcome Solomon Moshkevich as the company’s next CEO. In 15 years at Natera, Solomon has helped build nearly every part of our business and was one of the instrumental leaders in our expansion into oncology. He leads with integrity, rigor and a natural competitive spirit. I can think of no one better to lead Natera into its next chapter. And for the second consecutive time, an internal leader is stepping into the CEO role. This is a testament to the depth of this extraordinary team that we have built. Congratulations, Solomon, and thank you, Steve. natera.com/company/news/nate…

Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Nov 5

I’m grateful to Steve Chapman for his excellent leadership as Natera’s CEO, and excited to welcome Solomon Moshkevich as the company’s next CEO. 15 years at Natera, deep integrity and a true competitive spirit. The next chapter is in exceptional hands. natera.com/company/news/nate…

Natera avatar
⟳ Matthew Rabinowitz retweeted
Natera@NateraGenetics·Jul 1

We're partnering with Aveta Biomics on a new global Phase 3 trial to help patients with head and neck cancer. Together, we're combining our Signatera™ test, which detects molecular residual disease (MRD), with Aveta's APG-157 immunotherapy. The trial will incorporate serial Signatera testing to assess MRD and treatment response throughout therapy and follow-up. This partnership has the potential to advance the field and improve care for patients with head and neck cancer, which affects nearly 950,000 people globally each year.

Post attachment
Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Jul 27

The goal: combine a patient's whole genome with AI trained on clinical data, and you can finally offer interventions matched to their actual biology. Lifestyle interventions, done with genuine rigor, are more powerful than most drugs we prescribe. We've built modern medicine around the easier option because changing behavior at scale is hard. Genomics and AI change that.

0:50
Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Jul 24

25 million Americans are living with a rare disease. The average diagnosis takes 4 to 7 years — not because it's untestable, but because standard diagnostic tools aren't built to find it. 1 in 17 people will be affected by a rare disease in their lifetime. Most will spend years being told nothing is wrong. Whole-genome sequencing lets the biology tell you what's there. That's the infrastructure worth building.

Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Jul 22

Anthropic just launched Claude Science — an AI workbench unifying 60+ scientific databases for drug discovery, plus their own programs targeting long-neglected diseases untouched by pharma. The bottleneck in drug development has always been fragmentation and time. AI is starting to fix both. cnbc.com/2026/06/30/anthropi…

Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Jun 29

Two milestones in under two months: ➡️ A landmark bladder cancer update now recommends ctDNA-MRD testing using Signatera technology ➡️ Japan's PMDA approved Signatera in colorectal cancer — the country's first ever PMDA-approved MRD test Years of clinical evidence behind each one. Proud of the @NateraGenetics team and partners making MRD-guided care a reality for patients.

0:47
Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Jun 26

⁠There's a difference between building a company and changing how a field thinks. The second changes what you hire for, how you deploy capital, and what you're willing to be patient about. It's worth deciding early which one you're actually trying to do.

Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Jun 26

Panorama took years to become the standard of care. Signatera spent a long time being called experimental. Neither looked inevitable in year two or five.

Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Jun 26

We got things wrong too. We underestimated neural networks early on, and a key patent lapsed right before Google Brain proved the approach at scale. More instructive than most of the wins.

Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Jun 26

Coming in as a physicist meant building fluency across genetics, clinical medicine, and regulation from scratch. But not having a fixed idea of how things were supposed to work let me see connections people inside the field had stopped looking for.

Inside Precision Medicine avatar
⟳ Matthew Rabinowitz retweeted
Inside Precision Medicine@Inside_PM·Jun 10

Signatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care Pathway Signatera ctDNA testing bridges the gap from uncertainty to actionability by answering meaningful questions at each stage of the patient’s journey. Sponsored: @NateraGenetics hubs.li/Q04kN72X0

Matthew Rabinowitz avatar
Matthew Rabinowitz@MattRVerse·Jun 12

For most of medicine, diagnosis is confirmation: you have a hypothesis, you run a test, you get an answer. That model works well when you know what you're looking for. Rare disease breaks that model. Most patients spend years, sometimes decades, cycling through specialists and inconclusive workups before getting a diagnosis. Not because the disease is untestable, but because nobody thought to test for it. Whole-genome sequencing inverts the model. Instead of starting with a hypothesis, you sequence the entire genome and let the biology tell you what's there. Combined with AI that can interpret millions of variants at once, you can surface conditions that would never have appeared on a differential diagnosis. That's the foundation of the rare disease test and proactive health report. The goal is finding what hypothesis-driven medicine was never going to find.

0:27